JANX

Janux Therapeutics, Inc. (JANX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Unaudited Quarterly Report on Form 10-Q for Janux Therapeutics, Inc. for the period ended June 30, 2026. Janux is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and autoimmune diseases using its proprietary TRACTr, TRACIr, and ARM platforms. The company has no approved products and has not generated product revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $14.0 million in collaboration revenue for the six months ended June 30, 2026, compared to zero in the prior year period. This is entirely attributable to a new exclusive license and collaboration agreement with Bristol-Myers Squibb (BMS) entered into in January 2026.
• Operating Expenses: Total operating expenses remained relatively flat year-over-year ($79.9 million vs. $80.0 million). Research and Development (R&D) expenses decreased by $1.9 million, driven by reduced direct costs for specific programs (JANX011, JANX014, JANX008), partially offset by increased spending on preclinical programs.
• Liquidity Position: Cash and cash equivalents decreased from $52.3 million at year-end 2025 to $27.8 million at June 30, 2026. However, short-term investments increased from $914.2 million to $943.1 million, resulting in a total liquid asset base of approximately $971.7 million.
• Deferred Revenue: Current deferred revenue increased significantly to $35.1 million, reflecting the upfront and milestone payments received under the BMS agreement that have not yet been recognized as revenue.

Outlook, Management Commentary, and Risks

• BMS Collaboration: The $56.7 million transaction price with BMS includes a $15.0 million upfront payment and a $35.0 million developmental milestone payment. Revenue is recognized over time using a cost-to-cost method. The company estimates the remaining performance obligation will be satisfied over approximately 1.3 years.
• Merck Collaboration: No revenue was recognized from the Merck agreement in the current period as performance obligations for both collaboration targets were completed in March 2023 and August 2024, respectively.
• Clinical Pipeline:
  • JANX007: Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) is ongoing.
  • JANX014: Entered clinical evaluation in April 2026.
  • JANX011: Phase 1 study for autoimmune diseases initiated in February 2026.
  • JANX008: Discontinued in April 2026 following Phase 1a completion due to insufficient activity magnitude.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months. However, the company expects to incur substantial losses for the foreseeable future and will require additional financing to complete development and commercialization.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for future capital raises which may cause dilution, reliance on third-party manufacturers (including WuXi Biologics in China), and potential regulatory delays. The company also faces risks related to data privacy, cybersecurity, and geopolitical trade tensions.

Investor Verification Checklist

• Verify the specific terms and revenue recognition timeline of the BMS collaboration agreement, particularly the $35.0 million milestone payment conditions.
• Monitor the progress and safety data of the Phase 1 trials for JANX007, JANX011, and JANX014.
• Assess the company's cash burn rate relative to its $971.7 million liquid asset base to confirm the 12-month runway estimate.
• Review the status of the discontinued JANX008 program and its impact on overall R&D strategy.
• Check for any updates on the WuXi Biologics supply chain relationship given geopolitical risks mentioned in the filing.